StemMed

Executive Summary

StemMed is a Houston-based pre-clinical services company that provides state-of-the-art drug testing using a large panel of patient-derived xenograft (PDX) models for breast and pancreatic cancers. Founded in 2015, the company's breast cancer models are derived from an ethnically diverse patient population and encompass all clinically defined subtypes, including ER+, HER2+, and triple-negative cancers. By offering these specialized models, StemMed enables pharmaceutical and biotech clients to more accurately predict drug efficacy and toxicity in pre-clinical stages, potentially accelerating the development of targeted therapies and improving clinical trial success rates. The company operates in the oncology and cell therapy categories and remains privately held with a pre-clinical stage focus.

Upcoming Catalysts (preview)

• Q4 2026Expansion of PDX panel into additional cancer types (e.g., colorectal, lung)70% success
• Q3 2026Strategic partnership or service agreement with a top-20 pharmaceutical company60% success
• Q2 2026Securing Series A funding to scale operations and commercial reach50% success